🔗 Share this article

The recently developed medications for gonorrhoea in a generation are being hailed as a "huge turning point" in the battle against increasingly resistant strains of the infection, according to scientists.

An International Public Health Issue

Cases of gonorrhoea are on the rise around the world, with figures suggesting more than 82 million new cases per year. Especially elevated rates are reported in Africa and nations within the World Health Organization's designated area, which spans from Mongolia and China to New Zealand. Across England, cases have hit a all-time high, while figures across Europe in 2023 were triple the level compared to figures for 2014.

“The approval of new treatments for gonorrhoea is an important and timely step in the context of rising global incidence, escalating drug resistance and the very limited therapeutic options currently available.”

Public health authorities are deeply concerned about the increase in treatment-resistant strains. The WHO has listed it as a "high-priority threat". Ongoing monitoring found that resistance to primary antibiotics like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

Two New Treatment Options Gain Clearance

One new antibiotic, alternatively called Nuzolvence, was authorized by the US Food and Drug Administration in December for combating gonorrhoea. This disease can lead to significant complications, including the inability to conceive. Researchers believe that specific application of this new drug will help delay the development of resistance.

Gepotidacin, originating from the drugmaker GSK, was also approved in the same week. This medication, which is employed against UTIs, was shown in trials to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

A Novel Approach to Creation

This new treatment was the result of a innovative non-profit model for antibiotic development. The non-profit organisation GARDP collaborated with the pharmaceutical company Innoviva to bring it to fruition.

“This approval signifies a major breakthrough in the treatment of highly resistant gonorrhoea, which until now has been staying ahead of antibiotic development.”

Testing Data and Worldwide Availability

According to findings published in a prominent scientific publication, the new drug successfully treated more than 90% of genital gonorrhoea infections. This puts it on an comparable level with the existing first-line therapy, which combines an injection and a pill. The trial involved nearly 1,000 volunteers from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its collaboration, the non-profit has the ability to register and commercialise the drug in a wide range of regions with limited resources.

Clinicians directly involved have voiced positive views. Access to a one-pill regimen like this is described as a "critical tool" for managing the epidemic. This is considered vital to alleviate the strain of the illness for patients and to halt the transmission of extremely resistant gonorrhoea worldwide.